UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 273

Sortiert nach

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

Clinical cancer research, 2012-11, Vol.18 (22), p.6373-6383

2012

Link zum Volltext

Verfügbarkeit prüfen

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (13), p.3690-3701

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

Investigational new drugs, 2014-06, Vol.32 (3), p.436-444

2014

Link zum Volltext

Verfügbarkeit prüfen

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

Cell reports (Cambridge), 2014-01, Vol.6 (2), p.377-387

2014

Link zum Volltext

Verfügbarkeit prüfen

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

Journal of clinical oncology, 2012-03, Vol.30 (8), p.777-782

2012

Link zum Volltext

Verfügbarkeit prüfen

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

The lancet oncology, 2014-05, Vol.15 (6), p.656-666

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

Journal of clinical oncology, 2012-07, Vol.30 (19), p.2348-2353

2012

Link zum Volltext

Verfügbarkeit prüfen

FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors

PloS one, 2014-02, Vol.9 (2), p.e89388-e89388

2014

Link zum Volltext

Verfügbarkeit prüfen

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic

Clinical cancer research, 2014-12, Vol.20 (24), p.6336-6345

2014

Link zum Volltext

Verfügbarkeit prüfen

Body composition and survival in the early clinical trials setting

European journal of cancer (1990), 2013-10, Vol.49 (15), p.3068-3075

2013

Link zum Volltext

Verfügbarkeit prüfen

Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer

Annals of oncology, 2013-12, Vol.24 (12), p.3004-3011

2013

Link zum Volltext

Verfügbarkeit prüfen

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine

Journal of hematology and oncology, 2019-12, Vol.12 (1), p.145-145, Article 145

2019

Link zum Volltext

Verfügbarkeit prüfen

Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities

Cancer and metastasis reviews, 2015-12, Vol.34 (4), p.547-561

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies

Clinical cancer research, 2009-11, Vol.15 (22), p.7061-7068

2009

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer

Annals of oncology, 2015-07, Vol.26 (7), p.1346-1352

2015

Link zum Volltext

Verfügbarkeit prüfen

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response

BMC cancer, 2015-10, Vol.15 (1), p.713-713, Article 713

2015

Link zum Volltext

Verfügbarkeit prüfen

Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs

Annals of oncology, 2012-11, Vol.23 (11), p.2960-2963

2012

Link zum Volltext

Verfügbarkeit prüfen

Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer

Investigational new drugs, 2015-06, Vol.33 (3), p.621-631

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation

Annals of oncology, 2015-05, Vol.26 (5), p.1012-1018

2015

Link zum Volltext

Verfügbarkeit prüfen

First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors

Investigational new drugs, 2014-12, Vol.32 (6), p.1204-1212

2014

Link zum Volltext

Verfügbarkeit prüfen

Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing

American journal of clinical pathology, 2015-11, Vol.144 (5), p.713-721

2015

Link zum Volltext

Verfügbarkeit prüfen

Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy

Annals of oncology, 2013-03, Vol.24 (3), p.838-842

2013

Link zum Volltext

Verfügbarkeit prüfen

Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy

Annals of oncology, 2013-09, Vol.24 (9), p.2256-2261

2013

Link zum Volltext

Verfügbarkeit prüfen

Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience

Annals of oncology, 2012-08, Vol.23 (8), p.1963-1967

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 273

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(241)
Mit Volltextzugriff
(270)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(99)
Life Sciences & Biomedicine
(95)
Humans
(91)
Oncology
(90)
Female
(86)
Middle Aged
(77)
Male
(76)
Adult
(69)
Aged
(68)
Aged, 80 And Over
(42)
Neoplasms - Drug Therapy
(41)
Treatment Outcome
(38)
Tumors
(31)
Biological And Medical Sciences
(30)
Mutation
(30)
Medical Sciences
(29)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(27)
Young Adult
(24)
Medicine
(23)
Neoplasms - Pathology
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(103)
Cancer Research
(28)
Molecular Cancer Therapeutics
(21)
Oncotarget
(19)
Annals Of Oncology
(14)
Investigational New Drugs
(14)
Clinical Cancer Research
(9)
Cancer Chemotherapy And Pharmacology
(7)
Canadian Family Physician
(4)
Cancer
(4)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic

Body composition and survival in the early clinical trials setting

Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine

Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities

Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies

Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response

Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs

Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer

Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation

First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors

Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing

Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy

Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy

Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience

Suchergebnisse filtern